Skip to content

Long-term evaluation of neurogenic bladder and urodynamic function in cervical cancer patients after radical hysterectomy

Long-term evaluation of neurogenic bladder and urodynamic function in cervical cancer patients after radical hysterectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500108399
Enrollment
Unknown
Registered
2025-08-29
Start date
2025-09-08
Completion date
Unknown
Last updated
2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer

Interventions

Observation group:None

Sponsors

Department of Gynecological Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai 200092, China
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Adult patients (aged >= 18 years); 2) Patients who underwent laparoscopic radical hysterectomy for cervical cancer (regardless of whether adjuvant therapy was administered postoperatively and the specific adjuvant treatment regimen); 3) Patients with postoperative follow-up duration ranging from 3 months to 10 years; 4) No evidence of tumor recurrence at the time of inclusion; 5) Patients with clear consciousness and ability to complete questionnaires and urodynamic testing; 6) Willingness to participate in the study and provision of signed informed consent.

Exclusion criteria

Exclusion criteria: 1) Presence of chronic conditions affecting urinary function, such as diabetes or neurological disorders (e.g., Parkinson’s disease, multiple system atrophy, multiple sclerosis, spinal cord lesions). 2) History of preoperative urinary or bowel symptoms, pelvic organ prolapse surgery, anti-incontinence surgery, or bladder injury/surgery. 3) History of vesicoureteral reflux, hydronephrosis, recurrent urinary tract infections, or urethral stricture. 4) Perioperative complications, including bleeding, injury, reoperation, or postoperative vesicovaginal fistula.5) Contraindications to urodynamic testing. 6) Use of medications affecting voiding within the past three months.

Design outcomes

Primary

MeasureTime frame
prevalence of neurogenic bladder;

Secondary

MeasureTime frame
Quality of Life Score;

Countries

China

Contacts

Public ContactXiaoqing Guo

Shanghai First Maternity and Infant Hospital

Xiaoqing_Guo@tongji.edu.cn+86 181 1720 3488

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026